4DMT builds out case for wet AMD gene therapy with new Phase 2 data

4D Molecular Therapeutics presented new Phase 2 data for its wet AMD gene therapy, showing a durable response in a broad patient population, as it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Epigenetic insights into stroke-induced immunological changes

A stroke not only causes acute damage to the brain, but can also have long-term health implications for other organs – such as the heart.

July 23, 2024

Dexcom’s over-the-counter nod sets stage for broader CGM use

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. The Food and Drug Administration cleared the

March 7, 2024

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months – Biotech Investments

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months 22.01.2024 / 08:30 CET/CEST The

January 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.